Europe's CHMP gives thumbs-up to Lilly's Kisunla and Gilead's long-acting PrEP drug Yeytuo

25th July 2025 Uncategorised 0

Four months after giving Eli Lilly’s Alzheimer’s disease treatment Kisunla a thumbs-down, Europe’s CHMP has recommended it for approval, albeit in a restricted patient population. The regulator also backed Gilead’s breakthrough PrEP drug Yeytuo.

More: Europe's CHMP gives thumbs-up to Lilly's Kisunla and Gilead's long-acting PrEP drug Yeytuo
Source: fierce